Sareum Holdings Plc - Company Profile
Powered by 
All the data and insights you need on Sareum Holdings Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sareum Holdings Plc Strategy Report
- Understand Sareum Holdings Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
Headquarters
United Kingdom
Address
Unit 2a, Langford Arch, London Road, Pampisford, Cambridge, Cambridgeshire, CB223FX
Website
sareum.com
Telephone
44 1223 497700
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAR (LON)
EPS
XYZ
Net Income (2022)
XYZ
-47%
(2022 vs 2021)
Market Cap*
$34.4M
Net Profit Margin (2019)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Sareum Holdings Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline products: |
| Chk1 (Checkpoint Kinase 1): |
| Prostate |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Sareum Holdings Plc | Genus Plc | IXICO Plc | Scancell Holdings Plc | Physiomics Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Cambridge | Basingstoke | London | Oxford | Oxford |
| State/Province | Cambridgeshire | England | England | Oxfordshire | England |
| No. of Employees | 5 | 3,476 | 89 | 51 | 10 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tim Mitchell, Ph.D. | Chief Executive Officer | Senior Management | - | 61 |
| John Reader, Ph.D. | Chief Scientific Officer | Senior Management | - | 55 |
| Stephen Parker | Chairman | Non Executive Board | 2016 | 64 |
| Michael Owen, Ph.D. | Director | Non Executive Board | 2018 | 71 |
| Clive Birch | Director | Non Executive Board | 2018 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer